
About this episode
Join Professors McInnes and Nash as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at three key papers published in May 2022. Our first paper highlights investigations of imaging characteristics and clinically assess heel enthesitis in SpA. The second of today’s paper evaluates the real-world effectiveness and persistence of the IL-12/23 inhibitor ustekinumab. Finally, our third paper reports the efficacy and safety of deucravacitinib in patients with active PsA. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Get every episode summarized
Each time The IMID Forum publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The IMID Forum

Author Interview: Doctor Elise van Mulligen, September 2026
The IMID Forum
Sep 3, 202621:20pending

Discussing RA: Biologic effectiveness and treatment persistence in RA
The IMID Forum
Aug 27, 20268:52pending

Discussing PsA: Advances in Psoriatic Arthritis Management and Treatment Safety
The IMID Forum
Aug 20, 202624:22pending

Author Interview: Professor Axel Finckh and Associate Professor Bente Glintborg,...
The IMID Forum
Aug 13, 202626:58pending